Uncomplicated Urinary Tract Infections and Antibiotic Resistance—Epidemiological and Mechanistic Aspects
Abstract
:1. Introduction
2. Therapeutic Options
3. Antibiotic Resistance—Genetic and Mechanistic Basis
4. Resistance to Sulfonamides and Trimethoprim—Epidemiology and Mechanisms
5. Resistance to Fluoroquinolones—Epidemiology and Mechanisms
6. Mechanisms of Resistance to β-Lactam Antibiotics—Epidemiology and Mechanisms
7. Resistance to Fosfomycin—Epidemiology and Mechanisms
8. Resistance to Nitrofurantoin—Epidemiology and Mechanisms
9. Epidemiological Aspects of Multiple Drug Resistance in Urinary Tract Infections
Acknowledgements
Author Contributions
Conflicts of Interest
References
- Hooton, T.C. Uncomplicated urinary tract infection. N. Engl. J. Med. 2012, 366, 1028–1037. [Google Scholar] [CrossRef]
- Nicolle, L.; Anderson, P.A.M.; Conly, J.; Mainprize, T.C.; Meuser, J.; Nickel, J.C.; Senikas, V.M.; Zhanel, G.G. Uncomplicated urinary tract infection in women. Can. Fam. Phys. 2006, 52, 612–618. [Google Scholar]
- Stuck, A.K.; Täuber, M.G.; Schabel, M.; Lehmann, T.; Suter, H.; Mühlemann, K. Determinants of quinolone versus trimethoprim-sulfamethoxazole use for outpatient urinary tract infection. Antimicrob. Agents Chemother. 2012, 56, 1359–1363. [Google Scholar] [CrossRef]
- Kahlmeter, G.; Odén Poulsen, H. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: The ECO·SENS study revisited. Intern. J. Antimicrob. Agents 2012, 39, 45–51. [Google Scholar] [CrossRef]
- Schito, G.C.; Naber, K.G.; Botto, H.; Palou, J.; Mazzei, T.; Gualco, L.; Marchese, A. The ARESC study: An international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int. J. Antimicrob. Agents 2009, 34, 407–413. [Google Scholar] [CrossRef]
- Lee, D.S.; Choe, H.S.; Lee, S.J.; Bae, W.J.; Cho, H.J.; Yoon, B.I.; Cho, Y.H.; Han, C.H.; Jang, H.; Park, S.B.; et al. Antimicrobial susceptibility pattern and epidemiology of female urinary tract infections in South Korea, 2010–2011. Antimicrob. Agents Chemother. 2013, 57, 5384–5393. [Google Scholar] [CrossRef]
- Grabe, M.; Bjerklound-Johansen, T.E.; Bartoletti, R.; Wulf, B.; Cek, M.; Naber, K.G.; Pickard, R.S.; Tenke, P.; Wagenlehner, F.; Wullt, B. Guidelines for Urological Infections; European Association of Urology: Arnhem, The Netherlands, 2014. [Google Scholar]
- S3-Leitlinie AWMF-Register Nr. 043/044 (Deutsche Gesellschaft für Urologie (DGU), Deutsche Gesellschaft für Allgemeine und Familienmedizin (DEGAM), Deutsche Gesellschaft für Gynäkologie und Geburtsthilfe (DGGG), Deutsche Gesellschaft für Hygiene und Mikrobiologie (DGHM), Deutsche Gesellschaft für Infektiologie (DGI), Deutsche Gesellschft für Nephrologie (DGfN), Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG). Available online: http://www.awmf.org/uploads/tx_szleitlinien/043-044l_S3_Harnwegsinfektionen.pdf (accessed on 18 July 2014).
- Matic, I.; Radman, M.; Taddei, F.; Picard, B.; Doit, C.; Bingen, E.; Denamur, E.; Elion, J. Highly variable mutation rates in commensal and pathogenic Escherichia coli. Science 1997, 277, 1833–1834. [Google Scholar] [CrossRef]
- Gupta, A.; Kaul, A.; Tsolaki, A.G.; Kishore, U.; Bhakta, S. Mycobacterium tuberculosis: Immune evasion, latency and reactivation. Immunobiology 2012, 217, 363–374. [Google Scholar] [CrossRef]
- Davies, J.; Davies, D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 2010, 74, 417–433. [Google Scholar] [CrossRef]
- Yoneyama, H.; Katsumata, R. Antibiotic resistance in bacteria and its future for novel antibiotic development. Biosci. Biotechnol. Biochem. 2006, 70, 1060–1075. [Google Scholar] [CrossRef]
- Moreno, E.; Prats, G.; Sabate, M.; Perez, T.; Johnson, J.R.; Andreu, A. Quinolone, fluoroquinolone and trimethoprim/sulfamethoxazole resistance in relation to virulence determinants and phylogenetic background among uropathogenic Escherichia coli. J. Antimicrob. Chemother. 2006, 57, 204–211. [Google Scholar] [CrossRef]
- Starcic, E.M.; Rijavec, M.; Krizan-Hergouth, V.; Fruth, A.; Zgur-Bertok, D. Chloramphenicol- and tetracycline-resistant uropathogenic Escherichia coli (UPEC) exhibit reduced virulence potential. Int. J. Antimicrob. Agents 2007, 30, 436–442. [Google Scholar] [CrossRef]
- Linhares, I.; Raposo, T.; Rodrigues, A.; Almeida, A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: A ten-year surveillance study (2000–2009). BMC Infect. Dis. 2013, 13, e19. [Google Scholar]
- Neuzillet, Y.; Naber, K.G.; Schito, G.; Gualco, L.; Botto, H. French results of the ARESC study: Clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. Med. Mal. Infect. 2012, 42, 66–75. [Google Scholar] [CrossRef]
- Sköld, O. Resistance to trimethoprim and sulfonamides. Vet. Res. 2001, 32, 261–273. [Google Scholar] [CrossRef]
- Yun, M.K.; Wu, Y.; Li, Z.; Zhao, Y.; Waddell, M.B.; Ferreira, A.M.; Lee, R.E.; Bashford, D.; White, S.W. Catalysis and sulfa drug resistance in dihydropteroate synthase. Science 2012, 335, 1110–1114. [Google Scholar] [CrossRef]
- Bhabha, G.; Lee, J.; Ekiert, D.C.; Gam, J.; Wilson, I.A.; Dyson, H.J.; Benkovic, S.J.; Wright, P.E. A dynamic knockout reveals that conformational fluctuations influence the chemical step of enzyme catalysis. Science 2011, 332, 234–238. [Google Scholar] [CrossRef]
- Sköld, O. Sulfonamides and trimethoprim. Exp. Rev. Anti-Infect. Ther. 2010, 8, 1–6. [Google Scholar] [CrossRef]
- Lescat, M.; Calteau, A.; Hoede, C.; Barbe, V.; Touchon, M.; Rocha, E.; Tenaillon, O.; Médigue, C.; Johnson, J.R.; Denamur, E. A module located at a chromosomal integration hot spot is responsible for the multidrug resistance of a reference strain from Escherichia coli clonal group A. Antimicrob. Agents Chemother. 2009, 53, 2283–2288. [Google Scholar] [CrossRef]
- EARS-net. Available online: http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database (accessed on 18 July 2014).
- Heisig, P. Type II topoisomerases—Inhibitors, repair mechanisms and mutations. Mutagenesis 2009, 24, 465–469. [Google Scholar] [CrossRef]
- Pohlhaus, J.R.; Kreuzer, K.N. Norfloxacin-induced DNA-gyrase cleavage complexes block Escherichia coli replication forks, causing double-stranded breaks in vivo. Mol. Microbiol. 2005, 56, 1416–1429. [Google Scholar] [CrossRef]
- Heisig, P. Inhibitors of bacterial topoisomerases: Mechanisms of action and resistance and clinical aspects. Planta Med. 2001, 67, 3–12. [Google Scholar] [CrossRef]
- Strahilevitz, J.; Jacoby, G.A.; Hooper, D.C. Plasmid-mediated quinolone resistance: A multifaceted threat. Clin. Microbiol. Rev. 2009, 22, 664–689. [Google Scholar] [CrossRef]
- Emrich, N.C.; Heisig, A.; Stubbings, W.; Labischinski, H.; Heisig, P. Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance. J. Antimicrob. Chemother. 2010, 65, 2530–2533. [Google Scholar] [CrossRef]
- Cesaro, A.; Roth Dit Bettoni, R.; Lascols, C.; Merens, A.; Soussy, C.J.; Cambau, E. Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes. J. Antimicrob. Chemother. 2008, 61, 1007–1015. [Google Scholar] [CrossRef]
- Allou, N.; Cambau, E.; Massias, L.; Chau, F.; Fantin, B. Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob. Agents Chemother. 2009, 53, 4292–4297. [Google Scholar] [CrossRef]
- Jakobsen, L.V.; Cattoir, K.S.; Jensen, A.M.; Hammerun, P.; Nordmann, N.; Frimodt-Moller, N. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model. J. Antimicrob. Chemother. 2012, 67, 2438–2444. [Google Scholar] [CrossRef]
- Christiansen, N.; Nielsen, L.; Jakobsen, L.; Stegger, M.; Hansen, L.H.; Frimodt-Møller, N. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country. Microb. Drug Resist. 2011, 17, 395–406. [Google Scholar] [CrossRef]
- Jansaker, F.; Frimodt-Møller, N.; Sjögren, I.; Knudsen, J.D. Clinical and bacterial effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infection. J. Antimicrob. Chemother. 2014, 69, 769–772. [Google Scholar] [CrossRef]
- Bush, K.; Jacoby, G. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 2010, 54, 969–976. [Google Scholar] [CrossRef]
- Palzkill, T. Metallo-β-lactamase structure and function. Ann. NY Acad. Sci. 2013, 1277, 91–104. [Google Scholar]
- Paterson, D.L.; Bonomo, R.A. Extended-spectrum beta-lactamases: A clinical update. Clin. Microbiol. Rev. 2005, 18, 657–686. [Google Scholar] [CrossRef]
- Bush, K.; Fisher, J.F. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from Gram-negative bacteria. Ann. Rev. Microbiol. 2011, 65, 455–478. [Google Scholar] [CrossRef]
- Cagnacci, S.; Gualco, L.; Debbia, E.; Schito, G.C.; Marchese, A. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST1131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. Antimicrob. Agents Chemother. 2008, 46, 2605–2612. [Google Scholar]
- Falagas, M.E.; Kastoris, A.C.; Kapaskelis, A.M.; Karageorgopoulo, D.E. Fosfomycin for the treatment of multidrug-resistant including extended-spectrum β-lactamase producing Enterobacteriaceae infections: A systematic review. Lancet Infect. Dis. 2010, 10, 43–50. [Google Scholar] [CrossRef]
- Takahata, S.; Ida, T.; Hiraishi, T.; Sakakibara, S.; Maebashi, K.; Terada, S.; Muratani, T.; Matsumoto, T.; Nakahama, C.; Tomono, K. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int. J. Antimicrob. Agents 2010, 35, 333–337. [Google Scholar] [CrossRef]
- Kim, D.H.; Lees, W.J.; Kempsell, K.E.; Lane, W.S.; Duncan, K.; Walsh, C.T. Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to the antibiotic fosfomycin. Biochemistry 1996, 35, 4923–4928. [Google Scholar]
- Karageorgopoulos, D.E.; Wang, R.; Yu, X.H.; Falagas, M.E. Fosfomycin: Evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J. Antimicrob. Chemother. 2012, 67, 255–268. [Google Scholar] [CrossRef]
- Wachino, J.; Yamane, K.; Suzuki, S.; Kimura, K.; Arakawa, Y. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob. Agents Chemother. 2010, 54, 3061–3064. [Google Scholar] [CrossRef]
- Sato, N.; Kawamura, K.; Nakane, K.; Wachino, J.I.; Arakawa, Y. First detection of fosfomycin resistance gene fosA3 in CTX-M-producing Escherichia coli isolates from healthy individuals in Japan. Microb. Drug Resist. 2013, 19, 477–482. [Google Scholar] [CrossRef]
- Koulaouzidis, A.; Bhat, S.; Moschos, J.; Tan, C.; de Ramon, A. Nitrofurantoin-induced lung- and hepatotoxicity. Ann. Hepatol. 2007, 6, 119–121. [Google Scholar]
- Platell, J.L.; Cobbold, R.N.; Johnson, J.R.; Heisig, A.; Heisig, P.; Clabots, C.; Kusowski, M.A.; Trott, D.J. Commonality between fluoroquinolone-resistant sequence type ST131 extraintestinal Escherichia coli isolates from humans and companion animals in Australia. Antimicrob. Agents Chemother. 2011, 55, 3782–3787. [Google Scholar] [CrossRef]
- Peirano, G.; Pitout, D.D. Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: The worldwide emergence of clone ST131 O25:H4. Intern. J. Antimicrob. Agents 2010, 35, 316–321. [Google Scholar] [CrossRef]
- Rogers, B.A.; Sidjabat, H.E.; Paterson, D.L. Escherichia coli O25b-ST131: A pandemic multiresistant community-associated strain. J. Antimicrob. Agents 2011, 66, 1–14. [Google Scholar] [CrossRef]
- Clark, G.; Paszkiewicz, K.; Hale, J.; Weston, V.; Constantinidou, C.; Penn, C.; Achtman, M.; McNally, A. Genomic analysis uncovers a phenotypically diverse but genetically homogeneous Escherichia coli ST131 clone circulating in unrelated urinary tract infections. J. Antimicrob. Chemother. 2012, 67, 868–877. [Google Scholar] [CrossRef]
- Hawser, S.P.; Bouchillon, S.K.; Hoban, D.J.; Badal, R.E.; Hsueh, P.R.; Paterson, D.L. Emergence of high-levels of extended-spectrum-β-lactamase-producing gram-negative bacilli in the Asia-Pacific region: Data from the study for monitoring antimicrobial resistance trends (SMART) program 2007. Antimicrob. Agents Chemother. 2009, 53, 3280–3284. [Google Scholar] [CrossRef]
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Wiedemann, B.; Heisig, A.; Heisig, P. Uncomplicated Urinary Tract Infections and Antibiotic Resistance—Epidemiological and Mechanistic Aspects. Antibiotics 2014, 3, 341-352. https://doi.org/10.3390/antibiotics3030341
Wiedemann B, Heisig A, Heisig P. Uncomplicated Urinary Tract Infections and Antibiotic Resistance—Epidemiological and Mechanistic Aspects. Antibiotics. 2014; 3(3):341-352. https://doi.org/10.3390/antibiotics3030341
Chicago/Turabian StyleWiedemann, Bernd, Anke Heisig, and Peter Heisig. 2014. "Uncomplicated Urinary Tract Infections and Antibiotic Resistance—Epidemiological and Mechanistic Aspects" Antibiotics 3, no. 3: 341-352. https://doi.org/10.3390/antibiotics3030341